Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA

Key Points

• Frazier Life Sciences Management acquired 1.1 million Kailera Therapeutics shares worth approximately $24.2 million, representing about 0.85% of the company. Atlas Venture Life Science Advisors also purchased a new $113.9 million position.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $42.75, although ratings range from “Strong Buy” to “Sell.”
• Kailera shares opened at $16.23, near the lower end of their $15.15–$28.23 52-week range. The company reported a quarterly loss of $1.09 per share, missing estimates of a $0.74 loss.

Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,100,000 shares of the company's stock, valued at approximately $24,233,000. Frazier Life Sciences Management L.P. owned about 0.85% of Kailera Therapeutics at the end of the most recent reporting period.

Separately, Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics during the second quarter worth $113,923,000.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Leerink Partners started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an "outperform" rating and a $36.00 price target on the stock. Jefferies Financial Group began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a "buy" rating and a $48.00 price objective for the company. Wall Street Zen cut Kailera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Evercore assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an "outperform" rating on the stock. Finally, Zacks Research raised Kailera Therapeutics to a "hold" rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

KLRA stock opened at $16.23 on Monday. Kailera Therapeutics, Inc. has a 52 week low of $15.15 and a 52 week high of $28.23. The company has a market capitalization of $2.10 billion and a price-to-earnings ratio of -0.00. The company's fifty day simple moving average is $18.54.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). Research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Kailera Therapeutics Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

Want to see what other hedge funds are holding KLRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.